葡萄糖钠协同转运体 2 抑制剂与心血管系统：当前知识与未来展望》。

IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart International Pub Date : 2023-12-01 eCollection Date: 2023-01-01 DOI:10.17925/HI.2023.17.2.12

Ioannis Boutsikos, Eleftherios Beltsios, Bastian Schmack, Ioannis Pantazopoulos, Dimitrios G Chatzis

{"title":"葡萄糖钠协同转运体 2 抑制剂与心血管系统：当前知识与未来展望》。","authors":"Ioannis Boutsikos, Eleftherios Beltsios, Bastian Schmack, Ioannis Pantazopoulos, Dimitrios G Chatzis","doi":"10.17925/HI.2023.17.2.12","DOIUrl":null,"url":null,"abstract":"Diabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multiple effects of SGLT2 inhibitors on patients across the spectrum of cardiovascular diseases.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"17 2","pages":"12-18"},"PeriodicalIF":1.9000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10898587/pdf/","citationCount":"0","resultStr":"{\"title\":\"Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations.\",\"authors\":\"Ioannis Boutsikos, Eleftherios Beltsios, Bastian Schmack, Ioannis Pantazopoulos, Dimitrios G Chatzis\",\"doi\":\"10.17925/HI.2023.17.2.12\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Diabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multiple effects of SGLT2 inhibitors on patients across the spectrum of cardiovascular diseases.\",\"PeriodicalId\":12836,\"journal\":{\"name\":\"Heart International\",\"volume\":\"17 2\",\"pages\":\"12-18\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10898587/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Heart International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/HI.2023.17.2.12\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/HI.2023.17.2.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

糖尿病心肌病是一种公认的临床实体，反映了代谢底物与心肌功能之间的复杂关系。葡萄糖钠协同转运体 2（SGLT2）抑制剂是一种抗糖尿病药物，具有多种心脏保护作用。大型临床试验显示，它们对心力衰竭患者有益，可降低再住院率并改善肾功能。本综述旨在总结文献中有关 SGLT2 抑制剂对各种心血管疾病患者的多重作用的最新证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations.

Diabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multiple effects of SGLT2 inhibitors on patients across the spectrum of cardiovascular diseases.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Heart International Medicine-Cardiology and Cardiovascular Medicine

CiteScore

0.90

自引率

0.00%

发文量

审稿时长

7 weeks